Douglas Lane & Associates LLC Purchases 54,295 Shares of Zoetis Inc. $ZTS

Key Points

• Douglas Lane & Associates LLC increased its stake in Zoetis Inc. by 31.5%, purchasing an additional 54,295 shares during the second quarter, bringing its total shares to 226,847.
• Zoetis reported earnings of $1.76 per share for the last quarter, exceeding analyst expectations, with revenues reaching $2.46 billion, up 4.2% year-over-year.
• The company has received mixed ratings, with some analysts downgrading the stock while others maintain a "buy" rating, resulting in a consensus rating of "Moderate Buy" and an average price target of $200.88.

Douglas Lane & Associates LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 31.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 226,847 shares of the company's stock after buying an additional 54,295 shares during the period. Douglas Lane & Associates LLC owned 0.05% of Zoetis worth $35,377,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Lindbrook Capital LLC boosted its stake in Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after purchasing an additional 65 shares in the last quarter. Quotient Wealth Partners LLC boosted its stake in Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after purchasing an additional 72 shares in the last quarter. Broadway Wealth Solutions Inc. boosted its stake in Zoetis by 4.4% in the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after purchasing an additional 73 shares in the last quarter. Menard Financial Group LLC boosted its stake in Zoetis by 3.8% in the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after purchasing an additional 75 shares in the last quarter. Finally, Anchor Investment Management LLC boosted its stake in Zoetis by 4.9% in the 1st quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock worth $266,000 after purchasing an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Argus reissued a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Price Performance

NYSE:ZTS opened at $148.33 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $65.74 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. The company has a 50 day moving average price of $152.32 and a 200-day moving average price of $157.26. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.